이 보고서는 북미와 유럽의 12명의 주요 KOL(Key Opinion Leader)의 의견을 바탕으로 대장암(CRC) 치료의 최신 동향과 발전을 상세히 분석합니다. 이 보고서는 경구용 멀티키나아제 억제제, HER-2 억제제, 면역요법 등 현재의 치료법을 다루고 그 효과와 내약성을 평가합니다. 또한 유망한 파이프라인 제품, 진행 중인 임상시험의 잠재적 영향, 미래 치료 경로에 대해서도 조사합니다. 또한 CRC 시장의 도전과 기회도 다루고 있어 제약사들에게 가치 있는 관점을 제공합니다.
보고서에서 다루는 주요 브랜드
- Balstilimab/botensilimab
- Divarasib
- Enhertu(trastuzumab deruxtecan)
- Etrumadenant
- Fruzaqla (fruquintinib)
- Jemperli(dostarlimab)
- Keytruda(pembrolizumab)
- Krazati(adagrasib)
|
- Lenvima(lenvatinib)
- Lumakras(sotorasib)
- Opdivo/Yervoy(nivolumab/ipilimumab)
- RMC-98051/RMC-6236
- Stivarga(regorafenib)
- Tukysa(tucatinib)
- zanidatamab
- Zanzalintinib
|
기업
Amgen, Roche, GSK, AstraZeneca, Merck, Merck & Co., Bristol Myers Squibb, Jazz Pharmaceuticals, Genentech, Gilead Sciences, Daiichi Sankyo, Bayer, Array BioPharma, Leap Therapeutics, Exelixis, Mirati, Seagen, Vaccinogen, Arcus Biosciences, Ono Pharmaceutical, Innovative Cellular Therapeutics, Faron Pharmaceuticals, Agenus, Gritstone bio, Hutchmed, Cardiff Oncology, Akeso Biopharma, Carina Biotech, Redx Pharma, Revolution Medicines
목차
주요 요약
조사 목적
출시된 제품
경구 멀티 키나아제 억제제
- 주요 견해 요약
- Stivarga(regorafenib, Bayer)
- Fruzaqla(fruquintinib, HUTCHMED)
HER-2 억제제
- 주요 견해 요약
- Tukysa(tucatinib, Array BioPharma/Merck & Co./Seagen)
- Enhertu(trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo)
PD-1/CTLA-4 면역요법
- 주요 견해 요약
- Keytruda(pembrolizumab, Merck & Co.)
- Opdivo(nivolumab, BMS/Ono)
- Yervoy(ipilimumab, BMS)
KRAS 억제제
- 주요 견해 요약
- Krazati(adagrasib, BMS/Mirati Therapeutics)
후기 파이프라인약
경구 멀티 키나아제 억제제
HER-2 억제제
- 주요 견해 요약
- Zanidatamab(Jazz Pharmaceuticals)
KRAS 억제제
- 주요 견해 요약
- Lumakras(sotorasib, Amgen)
- GDC-6036(divarasib, Roche)
- Pan-KRAS inhibitors(RMC-98051 and RMC-6236, Revolution Medicines)
암 백신
- 주요 견해 요약
- OncoVAX(Vaccinogen)
- GRANITE(Gritstone bio)
체크포인트 억제제
- Jemperli(dostarlimab, GSK)
- Bavencio(avelumab, Merck KGaA)
- Tecentriq(atezolizumab, Roche/Genentech)
- LAG-3/PD-1 조합
- 주요 견해 요약
- Nivolumab + relatlimab(Bristol Myers Squibb)
- Pembrolizumab + favezelimab(MK-4280 A, Merck & Co.)
- 차세대 CTLA-4/PD-1 조합
- Botensilimab/balstilimab(Agenus)
- 신규 이중특이성, 삼중특이성 mAbs
- Cadonilimab(Akeso Biopharma)
- 주요 견해 요약
중기/초기 단계 파이프라인
- ADC와 기타 모달리티
- 주요 견해 요약
- CCR8 억제제
- TROP2 CAR로 조작된 IL-15 형질전환 제대혈(CB)-NK 세포
- 항클라우딘 18.2 mAbs
- 항CEACAM5 ADC
- Wnt 신호전달 억제제
- 주요 견해 요약
- Sirexatamab(DKN 01, Leap Therapeutics)
- Zamaporvint(RXC004, Redx Pharma)
- TIGIT 억제제
- 주요 견해 요약
- Tiragolumab(Genentech)
- Domvanalimab(Gilead)
- Vibostolimab(Merck)
- A2a/A2b 수용체 이중 길항제
- 주요 견해 요약
- Etrumadenant(Arcus Biosciences)
- 폴로 유사 키나아제 1 억제제
- 주요 견해 요약
- Onvansertib(Cardiff Oncology)
- CLEVER-1 억제제
- 주요 견해 요약
- Bexmarilimab(Faron Pharmaceuticals)
- CAR-T 요법
- 주요 견해 요약
- CNA3103(Carina Biotech)
- GCC19CART(Innovative Cellular Therapeutics)
향후 전망
- 주요 견해 요약
- 앞으로 종양 전문의들은 CRC의 분자적 특성을 더 잘 이해하고 치료 전략을 맞춤화할 수 있을 것으로 예측하고 있습니다.
부록
ksm
This report provides an in-depth analysis of the latest trends and developments in colorectal cancer (CRC) treatment, based on insights from 12 leading key opinion leaders (KOLs) in North America and Europe. The report covers current therapies, including oral multikinase inhibitors, HER-2 inhibitors, and immunotherapies, and evaluates their efficacy and tolerability. It also explores promising pipeline products, the potential impact of ongoing clinical trials, and future treatment pathways. Additionally, the report addresses the challenges and opportunities in the CRC market, offering valuable perspectives for pharmaceutical professionals.
Key brands covered in this report:
- Balstilimab/botensilimab
- Divarasib
- Enhertu (trastuzumab deruxtecan)
- Etrumadenant
- Fruzaqla (fruquintinib)
- Jemperli (dostarlimab)
- Keytruda (pembrolizumab)
- Krazati (adagrasib)
|
- Lenvima (lenvatinib)
- Lumakras (sotorasib)
- Opdivo/Yervoy (nivolumab/ipilimumab)
- RMC-98051/RMC-6236
- Stivarga (regorafenib),
- Tukysa (tucatinib)
- zanidatamab
- Zanzalintinib
|
Key questions answered:
- How are currently approved therapies for CRC perceived in terms of efficacy and tolerability?
- Which drug class has the greatest potential to impact prescribing trends?
- Which pipeline products are the most promising, and how will they affect the market?
- Which clinical trials have the potential to impact future CRC treatment protocols?
- How will the diagnosis of mCRC evolve in the future?
- What are the most promising future treatments for CRC?
- What are the major challenges and opportunities in the mCRC market?
Companies:
Amgen, Roche, GSK, AstraZeneca, Merck, Merck & Co., Bristol Myers Squibb, Jazz Pharmaceuticals, Genentech, Gilead Sciences, Daiichi Sankyo, Bayer, Array BioPharma, Leap Therapeutics, Exelixis, Mirati, Seagen, Vaccinogen, Arcus Biosciences, Ono Pharmaceutical, Innovative Cellular Therapeutics, Faron Pharmaceuticals, Agenus, Gritstone bio, Hutchmed, Cardiff Oncology, Akeso Biopharma, Carina Biotech, Redx Pharma, Revolution Medicines.
Table of Contents
Executive summary
Research objectives
Marketed products
Oral multikinase inhibitors
- Key insights summary
- Stivarga (regorafenib; Bayer)
- Fruzaqla (fruquintinib; HUTCHMED)
HER-2 inhibitors
- Key insights summary
- Tukysa (tucatinib; Array BioPharma/Merck & Co./Seagen)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
PD-1/CTLA-4 immunotherapies
- Key insights summary
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; BMS/Ono)
- Yervoy (ipilimumab; BMS)
KRAS inhibitors
- Key insights summary
- Krazati (adagrasib; BMS/Mirati Therapeutics)
Late-stage pipeline drugs
Oral multikinase inhibitors
HER-2 inhibitors
- Key insights summary
- Zanidatamab (Jazz Pharmaceuticals)
KRAS inhibitors
- Key insights summary
- Lumakras (sotorasib; Amgen)
- GDC-6036 (divarasib; Roche)
- Pan-KRAS inhibitors (RMC-98051 and RMC-6236; Revolution Medicines)
Cancer vaccines
- Key insights summary
- OncoVAX (Vaccinogen)
- GRANITE (Gritstone bio)
Checkpoint inhibitors
- Jemperli (dostarlimab; GSK)
- Bavencio (avelumab; Merck KGaA)
- Tecentriq (atezolizumab; Roche/Genentech)
- LAG-3/PD-1 combinations
- Key insights summary
- Nivolumab + relatlimab (Bristol Myers Squibb)
- Pembrolizumab + favezelimab (MK-4280A; Merck & Co.)
- Next-generation CTLA-4/PD-1 combinations
- Botensilimab/balstilimab (Agenus)
- Novel bispecific and trispecific mAbs
- Cadonilimab (Akeso Biopharma)
- Key insights summary
Mid/early-stage pipeline
- ADCs and other modalities
- Key insights summary
- CCR8 inhibitors
- TROP2 CAR engineered IL-15- transduced cord blood (CB)-NK cells
- Anti-claudin18.2 mAbs
- Anti-CEACAM5 ADCs
- Wnt signalling inhibitors
- Key insights summary
- Sirexatamab (DKN 01; Leap Therapeutics)
- Zamaporvint (RXC004; Redx Pharma)
- TIGIT inhibitors
- Key insights summary
- Tiragolumab (Genentech)
- Domvanalimab (Gilead)
- Vibostolimab (Merck)
- Dual antagonist of A2a/A2b receptors
- Key insights summary
- Etrumadenant (Arcus Biosciences)
- Polo-like-kinase 1 inhibitor
- Key insights summary
- Onvansertib (Cardiff Oncology)
- CLEVER-1 inhibitors
- Key insights summary
- Bexmarilimab (Faron Pharmaceuticals)
- CAR-Ts Therapies
- Key insights summary
- CNA3103 (Carina Biotech)
- GCC19CART (Innovative Cellular Therapeutics)
Future outlook
- Key insights summary
- In the future, oncologists anticipate better molecular characterisation of CRC to tailor treatment strategies
Appendix
